IVD Medical Holding Ltd (1931) Fair Value & Analysis
Healthcare · HK · Market cap HK$1.0B
Fair value as of: Aug 15, 2026
From 16 valuation models · updated 2 days ago
Share price −8.6% over the past month.
Below-average quality, screening 11% undervalued on our models.
What matters now
- A fairly wide model range (HK$0.4200 to HK$0.8300) leaves room in how you read the outcome.
- Our model range runs from HK$0.4200 (bear) to HK$0.8300 (bull), base HK$0.6500. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 22/100 (below-average quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 15, 2026.
How to read this chart
60‑month range HK$0.5700 – HK$11.23 · fair‑value band HK$0.4200 – HK$0.8300 · the HK$0.5850 price screens below the HK$0.6500 fair value. Dashed = 300-day average. As of Aug 15, 2026.
Analysis
IVD Medical Holding Ltd (1931) currently trades at HK$0.5850, while our model-based Fair Value estimate is HK$0.6500, implying the stock looks roughly 11.1% undervalued today. The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, IVD Medical Holding Ltd generated revenue of HK$2.8B at a net margin of 1.2%. Revenue declined 14.3% year over year. It earns a return on equity of 1.1%. Net debt stands at HK$1.4B. Fundamentals as of Aug 15, 2026
Our scenario range runs from HK$0.4200 (bear case) to HK$0.8300 (bull case); at HK$0.5850, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -7% fair-value upside, at 11%, 1931 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Asset-Based (HK$1.23) versus Earnings-Based (HK$0.3800). Highest evidence: Residual Income (76).
Notify me when 1931 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 23 · Market factors (momentum, volatility) 16
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
ETHK Labs Inc., an investment holding company, distributes In vitro diagnostic (IVD) products in Mainland China and internationally. The company operates through three segments: Distribution Business, After-sales Services, and Self-branded Products Business.
Full company description
ETHK Labs Inc., an investment holding company, distributes In vitro diagnostic (IVD) products in Mainland China and internationally. The company operates through three segments: Distribution Business, After-sales Services, and Self-branded Products Business. It offers IVD analysers, reagents, and other consumables for various IVD testing categories, including hematology and body fluid, immunoassay, clinical chemistry, immunology, microbiology, and point-of-care testing. The company also provides haemostasis products; solution services to the clinical laboratories of hospitals; and maintenance and repair, installation, and end customer training services. In addition, it researches, develops, manufactures, and sells IVD analysers and reagents. The company offers its products to hospitals and healthcare institutions, logistics providers, and distributors. The company was formerly known as IVD Medical Holding Limited and change its name to ETHK Labs Inc. in December 2025. ETHK Labs Inc. was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
IVD Medical Holding Ltd reported revenue of HK$2.8B in FY2025 versus HK$2.7B in FY2021, a compound +0.8%/yr. Reported net income was HK$34.9M in FY2025, compounding −33.1%/yr from FY2021.
Watch 1931: get an alert when its fair value changes →
Peer Group
Medical Distribution · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $878.73 | $819.31 | -7% |
| Cencora, Inc COR | $314.17 | $211.07 | -33% |
| Cardinal Health, Inc CAH | $234.16 | $141.77 | -39% |
| Henry Schein, Inc HSIC | $90.74 | $71.70 | -21% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.56 | ¥33.96 | +105% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | -24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.49 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 80.00 | kr 28.26 | -65% |
Compare IVD Medical Holding Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is IVD Medical Holding Ltd (1931) overvalued or undervalued?
What is the fair value of 1931?
What is the quality score of 1931?
What is the revenue of IVD Medical Holding Ltd (1931)?
What is the net profit margin of 1931?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track IVD Medical Holding Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.